5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.
about
The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotypeEmerging targets in lipid-based therapyGene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease.FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo .Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases.Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer's disease.Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles.Degradation of gamma secretase activating protein by the ubiquitin-proteasome pathway.Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidencePharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy.Gene Therapy Models of Alzheimer's Disease and Other Dementias.5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5.Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg miceThe influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence.5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease.GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome.Combined Administration of Melissa officinalis and Boswellia serrata Extracts in an Animal Model of Memory.Modulation of lipopolysaccharide-induced memory insult, γ-secretase, and neuroinflammation in triple transgenic mice by 5-lipoxygenase.Homocysteine modulates 5-lipoxygenase expression level via DNA methylation.Novel lipid signaling pathways in Alzheimer's disease pathogenesis.Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer's phenotype.The Lipoxygenases: Their Regulation and Implication in Alzheimer's Disease.Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases.SIRT1 Overexpression in Mouse Hippocampus Induces Cognitive Enhancement Through Proteostatic and Neurotrophic Mechanisms.The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target.The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy.Overexpression of 5-Lipoxygenase Worsens the Phenotype of a Mouse Model of Tauopathy.Brain 5-lipoxygenase over-expression worsens memory, synaptic integrity, and tau pathology in the P301S mice.Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3β kinase: implications for Alzheimer's disease.Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice.Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.
P2860
Q26999358-F950C814-92F2-48C6-BADB-C6A68DD019DEQ28655456-467AD950-55AF-4D92-99B2-AC8C58C72E60Q30540833-2425DB26-D388-4D12-89F6-E38E992F3492Q33647503-89C1BB3B-C59A-476F-9BB4-50F8EF8523B8Q33832795-94746AAB-1929-474B-960E-58ED650C6A29Q34575734-5945629A-761A-4140-8C20-41E4D5D62B10Q34948311-6B0D6528-1EB0-41A9-86F2-F76F9329E0E2Q35417877-4178B661-3E5D-4125-9743-0109237DC0A5Q35745694-5DD47223-27B2-4150-9C4E-EF0DBDE38938Q35929097-D2BC99EB-B9CC-4D8C-9173-521ABFADBCAEQ36524290-6F6BED2F-BA54-440F-83E1-BD1403492693Q36680982-B3C1C266-86F8-44D7-B914-DE23F5B8558BQ37022025-4296D123-CA01-4CCD-890C-D3B7970C3144Q37053817-8DE054E4-3A8D-4368-9388-2F18AFE200F5Q37093350-96ABC8A9-90B7-467D-9126-293B16A73E04Q37184747-667DF2C0-EE6C-4773-81C7-C85870617FEEQ37396723-0A3461D8-7183-49C3-B76A-39960C161DD5Q37627877-F65A1C05-6020-4F6C-91FC-12BB8B0098F5Q37678192-31E7C6F6-0132-43CD-99A4-091EE2E4AB7AQ37678676-67B75FEE-6CF2-4E1F-9AAB-5FBC916DB189Q37739453-94E7030B-B080-480B-93BF-8FC1571C9DF3Q38671719-1A0461C6-0063-4ECA-A160-FFBCE85F68F7Q38728679-E366EE18-5219-4122-A714-7E822A00AF78Q38747012-47D18505-671F-4EDF-A4E5-89407EF7D685Q38785505-67CE209E-64FD-49C6-B919-1161A6FADC03Q47284015-FA154F1B-A9BF-4D4F-B54B-75981A97D544Q47412565-6575C858-A680-410C-B177-5278A0D060D6Q47438369-B838352F-2DF5-4F36-A328-DE27E7CAA64EQ48332447-F4DCA1AC-8CAB-4C51-811C-2C647CF69EF6Q51731158-4588FE3F-6EAE-4B63-B20D-FC40CA0F654CQ54979137-68D1E332-E910-429B-A981-251596B3D1A4
P2860
5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
5-Lipoxygenase gene transfer w ...... se model of Alzheimer disease.
@ast
5-Lipoxygenase gene transfer w ...... se model of Alzheimer disease.
@en
type
label
5-Lipoxygenase gene transfer w ...... se model of Alzheimer disease.
@ast
5-Lipoxygenase gene transfer w ...... se model of Alzheimer disease.
@en
prefLabel
5-Lipoxygenase gene transfer w ...... se model of Alzheimer disease.
@ast
5-Lipoxygenase gene transfer w ...... se model of Alzheimer disease.
@en
P2093
P2860
P356
P1433
P1476
5-Lipoxygenase gene transfer w ...... se model of Alzheimer disease.
@en
P2093
Carolina Ceballos-Diaz
Domenico Praticò
Phillip F Giannopoulos
Todd E Golde
P2860
P304
P356
10.1002/ANA.23642
P577
2012-09-01T00:00:00Z